Alcon Announces Positive Topline Results From Phase 3 COMET Trials of AR-15512, a Novel Topical Drug Candidate for Dry Eye

AR-15512, a topical transient receptor potential melastatin 8 (TRPM8) agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease. In both pivotal efficacy and safety studies (COMET-2 and COMET-3), the primary endpoint was achieved (p <0.0001) 


Clinical Trial Information about COMET-4, found here


AR-15512 is an investigational drug product that has not been submitted to the U.S. Food and Drug Administration (FDA) for approval and is not currently commercially available. 


AR-15512 Timeline

COMET: Clinical Development Program for AR-15512

You are on a website for Health Care Professionals in the United States

By clicking below “OK” you acknowledge that this site is intended for Health Care professionals only